Endocrine Disorders
Fetal and Neonatal Thyroid Physiology & Transplacental Transfer
- Maternal-Fetal Thyroid Dynamics & Hypothyroxinemia: ((NEND001)): Maternal TSH does not cross the placenta due to large molecular size. Thyroxine (T4) and triiodothyronine (T3) cross in limited amounts because they are inactivated by placental type 3 deiodinase (converting T4 to inactive reverse T3). In fetal hypothyroxinemia, a compensatory increase in maternal-to-fetal transfer of T4 occurs in the second and third trimesters to protect the fetus.
- Preterm Neonatal Thyroid Physiology: ((NEND002)): Compared to term infants, preterm infants (especially <31 weeks) exhibit a blunted TSH surge with a reduced rise in T4 and T3 levels due to hypothalamic-pituitary-thyroid axis immaturity.
- Congenital Hypothyroidism Screening in Preterm Infants: ((NEND006)): Infants with birth weight <1500 g require repeat screening at 2, 6, and 10 weeks of age regardless of initial results due to delayed TSH elevation risk.
Congenital Hypothyroidism: Etiology, Genetics, and Diagnosis
- Genetics of Thyroid Dysgenesis: ((((NEND003)) · ((NEND004)))): Thyroid dysgenesis (agenesis, hypoplasia, ectopy) is predominantly sporadic (low recurrence risk). Candidate transcription factor mutations include PAX8, FOXE1, NKX2.1, and NKX2.5. GNAS (encoding Gs$\alpha$ protein, associated with pseudohypoparathyroidism) is not involved in thyroid embryogenesis.
- TSH Receptor Resistance: ((NEND005)): Persistent hyperthyrotropinemia with low-normal free T4 and a small, normally located gland without goiter indicates TSH receptor mutations (impaired receptor signaling).
- Thyroid Hypoplasia vs. Dyshormonogenesis: ((NEND016)): Low serum thyroglobulin with detectable thyroid tissue favors thyroid hypoplasia. Conversely, dyshormonogenesis typically presents with goiter and elevated thyroglobulin levels.
- Iodine-Induced Hypothyroidism: ((NEND017)): Preterm neonates exposed to excess iodine develop primary hypothyroidism via the Wolff-Chaikoff effect, characterized by a normal-sized gland, elevated thyroglobulin, and high urinary iodine.
- Central Hypothyroidism & Pituitary Evaluation: ((NEND018)): Low T4 with inappropriately normal/low TSH, hypoglycemia, micropenis, and midline facial defects indicates central hypothyroidism. Mandatory action: Measure serum cortisol and growth hormone levels before starting L-thyroxine to avoid precipitating an adrenal crisis.
- Transient Hypothyroxinemia of Prematurity: ((((NEND007)) · ((NEND019)))): Extremely low birth weight/critically ill infants may present with delayed TSH elevation. Initial newborn screens can be falsely normal. Treatment monitoring requires T4 normalization within 1 week and TSH within 2 weeks of starting therapy; first follow-up FT4 at 1–2 weeks, and assessments every 1–3 months during the first year of life.
Maternal Thyroid Disease in Pregnancy & Neonatal Management
- Hyperthyroidism in Pregnancy & Antithyroid Drugs: ((((NEND008)) · ((NEND011)) · ((NEND012)))): - First trimester: Propylthiouracil (PTU) is preferred over methimazole to avoid embryopathy (cutis aplasia). - Second trimester onwards: Switch to methimazole because PTU carries a high risk of severe maternal hepatotoxicity. - In cases of agranulocytosis/complications requiring discontinuation of antithyroid drugs, surgical thyroidectomy in the second trimester is the definitive therapy. Radioactive iodine is strictly contraindicated in pregnancy.
- Fetal Graves' Disease & Surveillance: ((((NEND013)) · ((NEND014)))): Transplacental TSH receptor-stimulating antibodies can cause fetal hyperthyroidism independently of maternal thyroid control. Surveillance requires serial fetal heart rate monitoring and ultrasound for fetal goiter. Neonates born to mothers with Graves' disease treated with antithyroid drugs may show transient neonatal thyrotoxicosis (as maternal drugs wash out in days 1–4) followed by neonatal hypothyroidism as maternal antibodies clear.
- Trimester-Specific TSH Ranges: ((NEND015)): Maternal hypothyroidism screening utilizes trimester-specific TSH reference ranges (first trimester: 0.1–2.5 mIU/L; second: 0.2–3.0 mIU/L; third: 0.3–3.0 mIU/L).
Gestational Diabetes Mellitus (GDM) & Fetal Growth
- GDM Risk Factors & Fetal Monitoring: ((((NEND009)) · ((NEND020)))): - Risk factors include advanced maternal age, multiparity, short stature, and multifetal gestation (younger maternal age is not a risk factor). - Fetal abdominal circumference (AC) >70th percentile after 29–30 weeks indicates fetal hyperinsulinemia and disproportionate macrosomia despite borderline maternal glycemic control, mandating escalation to insulin therapy.
Disorders of Sex Development (DSD) & Ambiguous Genitalia
- Timing of Hormonal Evaluation: ((NEND021)): Hormonal assays (17-OHP, LH, testosterone) in newborns with suspected DSD must be interpreted when obtained after 48–72 hours of life to avoid confounding by early postnatal hormonal surges.
- 46,XY Complete Gonadal Dysgenesis (Swyer Syndrome): ((NEND022)): Defective SRY-mediated testicular differentiation leads to absent AMH and testosterone, persistent Müllerian structures (uterus), and a 46,XY karyotype. The risk of germ cell tumors reaches ~30%, requiring gonadectomy.
- Androgen Synthesis Defects vs. Metabolism Defects: ((NEND023)): - Androgen synthesis defects (low testosterone, elevated precursors) include 17$\beta$-hydroxysteroid dehydrogenase, 3$\beta$-hydroxysteroid dehydrogenase, and 17$\alpha$-hydroxylase deficiencies. - 5$\alpha$-reductase deficiency is a defect in androgen metabolism (normal testosterone, impaired conversion to dihydrotestosterone).
- Micropenis & Panhypopituitarism Management: ((NEND024)): Neonates presenting with micropenis, hypoglycemia, and panhypopituitarism require immediate intravenous hydrocortisone for life-threatening adrenal insufficiency before initiating testosterone or growth hormone therapy.
- Evaluation Threshold for DSD: ((NEND025)): Any combination of cryptorchidism with proximal hypospadias or micropenis mandates a full DSD workup (karyotype and hormonal profile) regardless of electrolyte stability or normal initial imaging.
- (A) Free passage of maternal TSH across the placenta
- (B) Increased transplacental passage of maternal T3 to the fetus
- (C) Placental conversion of T4 to active T3 by type 3 deiodinase
- (D) Increased maternal to fetal transfer of T4 in later trimesters
💡 Click to Reveal Answer & Nelson Rationale
The placenta regulates fetal thyroid hormone exposure by selective permeability and metabolic inactivation. Thyrotropin-releasing hormone and iodine cross the placenta freely, while TSH does not cross due to its large size, preventing direct maternal control of fetal thyroid function. Thyroxine crosses the placenta in limited amounts because it is inactivated by placental type 3 deiodinase, which converts T4 into inactive reverse T3. Triiodothyronine is also inactivated and has minimal placental transfer. However, in the setting of fetal hypothyroxinemia, there is a compensatory increase in maternal to fetal transfer of T4, especially in the second and third trimesters. This adaptive mechanism ensures availability of thyroid hormone to the fetus and helps protect against the adverse effects of fetal hypothyroidism, particularly on neurodevelopment.
- (A) Similar TSH surge but exaggerated rise in T3 and T4 levels
- (B) Blunted TSH surge with reduced rise in T3 and T4 levels
- (C) Absent TSH surge with markedly elevated T3 and normal T4 levels
- (D) Normal TSH surge with delayed increase in T4 and T3 after 1 week
💡 Click to Reveal Answer & Nelson Rationale
In term neonates, birth is followed by a rapid and marked TSH surge within the first few hours, which stimulates a significant increase in T4 and T3 levels. In preterm infants, although the general pattern of postnatal thyroid hormone changes is similar, the magnitude of the TSH surge is reduced. This results in a blunted increase in T4 and T3 levels compared to term infants. In very preterm infants, especially those less than 31 weeks gestation, the TSH surge may be absent, leading to even more pronounced abnormalities such as a fall in T4 levels. These differences reflect immaturity of the hypothalamic–pituitary–thyroid axis and reduced thyroid gland responsiveness.
- (A) PAX8
- (B) FOXE1
- (C) NKX2.1
- (D) GNAS
💡 Click to Reveal Answer & Nelson Rationale
Thyroid dysgenesis is rarely associated with mutations in transcription factors that are essential for normal thyroid embryogenesis. These include PAX8, FOXE1, NKX2.1, and NKX2.5, all of which play a critical role in thyroid gland development, migration, and differentiation. Mutations in these genes can result in agenesis, hypoplasia, or ectopy of the thyroid gland. In contrast, GNAS is not involved in thyroid embryogenesis. It encodes a G protein involved in signal transduction and is associated with disorders such as pseudohypoparathyroidism. Therefore, it is least likely to be implicated in thyroid dysgenesis.
- (A) High recurrence risk due to autosomal dominant inheritance
- (B) Moderate recurrence risk due to multifactorial inheritance
- (C) Low recurrence risk as most cases are sporadic
- (D) High recurrence risk due to X-linked inheritance
💡 Click to Reveal Answer & Nelson Rationale
Thyroid dysgenesis is the most common cause of congenital hypothyroidism and includes agenesis, hypoplasia, and ectopic thyroid tissue due to failure of normal descent. The majority of cases are sporadic with no identifiable genetic inheritance pattern. As a result, there is no significant increase in recurrence risk in subsequent siblings. This is an important counseling point for parents, as the condition typically occurs as an isolated developmental anomaly rather than a familial disorder.
- (A) Loss-of-function mutation in the stimulatory Gsα subunit impairing intracellular signaling
- (B) Mutation in the TSH receptor leading to impaired receptor function
- (C) Mutation in TRH receptor leading to reduced pituitary TSH secretion
- (D) Mutation in thyroglobulin leading to defective thyroid hormone synthesis
💡 Click to Reveal Answer & Nelson Rationale
This clinical scenario describes TSH resistance, characterized by persistently elevated TSH with normal or low-normal T4 and a small, normally located thyroid gland. The absence of goiter indicates ineffective TSH action rather than excessive stimulation. The most common cause of this condition is a mutation in the TSH receptor, which leads to impaired receptor function and reduced thyroid responsiveness despite elevated circulating TSH. As a result, thyroid hormone production is inadequate, and gland growth is not stimulated. Rarely, post-receptor defects such as mutations in the stimulatory Gsα subunit can produce a similar phenotype, but these are uncommon. The key concept is defective TSH signaling at the receptor level leading to thyroid hyporesponsiveness.
- (A) All newborns should be screened only after 72 hours of life to avoid false-positive results
- (B) If a newborn is transferred to another hospital, repeat screening is unnecessary if clinical status is stable
- (C) Infants with birth weight <1500 g require repeat screening only if initial TSH is abnormal
- (D) Infants with birth weight <1500 g require repeat screening at 2, 6, and 10 weeks of age
💡 Click to Reveal Answer & Nelson Rationale
Newborn screening for congenital hypothyroidism is ideally performed between 48 and 72 hours of life, but earlier testing may be required due to early discharge. Screening should not be delayed beyond 72 hours as early diagnosis is crucial. Infants with birth weight less than 1500 g are at increased risk of delayed TSH elevation and therefore require repeat screening at 2, 6, and 10 weeks of age irrespective of initial results. Additionally, if an infant is transferred to another hospital, it must be confirmed that screening has been performed; otherwise, a specimen should be sent by the receiving hospital.
- (A) T4 should normalize within 1 week and TSH within 2 weeks of starting therapy
- (B) First follow-up with FT4 measurement should be done 1 to 2 weeks after starting treatment
- (C) After normalization of TSH, follow-up every 6 to 12 months is recommended during the first year of life
- (D) Thyroid function tests should be repeated 4 to 6 weeks after any change in L-thyroxine dose
💡 Click to Reveal Answer & Nelson Rationale
In congenital hypothyroidism, rapid normalization of thyroid hormone levels is critical for optimal neurodevelopment. T4 levels should normalize within 1 week and TSH within 2 weeks after initiating therapy. The first follow-up with FT4 estimation is recommended at 1 to 2 weeks after starting treatment. Thereafter, frequent monitoring is required, with assessments every 2 weeks until TSH normalizes. During the first year of life, follow-up should be done every 1 to 3 months, not 6 to 12 months. Thyroid function tests should also be repeated 4 to 6 weeks after any change in L-thyroxine dose or formulation.
- (A) Methimazole achieves lower breast milk-to-plasma ratio compared to PTU, thereby minimizing neonatal exposure
- (B) PTU undergoes enterohepatic circulation in the infant leading to accumulation and toxicity
- (C) PTU is associated with risk of severe hepatotoxicity in the mother despite relatively limited transfer into breast milk
- (D) Methimazole has a shorter half-life allowing rapid titration and reduced steady-state exposure in breastfed infants
💡 Click to Reveal Answer & Nelson Rationale
Both methimazole and PTU are excreted into breast milk in small amounts and are generally considered safe in lactating women at recommended doses. However, methimazole is preferred because PTU carries a significant risk of severe hepatotoxicity in the mother. This risk outweighs any theoretical pharmacokinetic advantages of PTU, such as slightly lower milk transfer. Therefore, safety considerations, particularly maternal hepatotoxicity, drive the preference for methimazole.
- (A) Younger maternal age at conception
- (B) Multigravida status of mother
- (C) Maternal short stature
- (D) Multifetal gestation (twin pregnancy)
💡 Click to Reveal Answer & Nelson Rationale
Gestational diabetes mellitus is associated with several maternal risk factors that reflect increased insulin resistance or adverse metabolic milieu. These include high parity (multigravida status), maternal short stature, and multifetal gestation, all of which are recognized contributors. In contrast, advanced maternal age is a known risk factor, whereas younger maternal age is not associated with increased risk and may be relatively protective. Therefore, younger maternal age is the least likely to be a risk factor among the given options. **Table: Risk Factors for Gestational Diabetes MellitusD** ![[41c01a8d_medium_table__2__1778132722.png]]
- (A) Normal finding in term female neonates
- (B) Suggestive of second-trimester androgen exposure
- (C) Suggestive of first-trimester androgen exposure
- (D) Indicative of estrogen excess during late gestation
💡 Click to Reveal Answer & Nelson Rationale
The anogenital ratio is an important clinical measure used to assess androgen exposure in utero. It is calculated as the distance between the anus and the posterior fourchette divided by the distance between the anus and the base of the phallus. In normal female neonates, this ratio is less than 0.5. A ratio greater than 0.5 indicates posterior labioscrotal fusion, which reflects exposure to androgens during early fetal development. The first trimester is the critical period for external genital differentiation, and androgen exposure during this time leads to structural changes such as fusion of labioscrotal folds. Therefore, an elevated anogenital ratio is a marker of first-trimester androgen exposure.
- (A) Continue propylthiouracil but decrease the dose by 10%
- (B) Switch to methimazole
- (C) Add propranolol and continue propylthiouracil
- (D) Continue propylthiouracil but decrease the dose by 50%
💡 Click to Reveal Answer & Nelson Rationale
Management of hyperthyroidism in pregnancy requires trimester-specific drug selection. Propylthiouracil is preferred during the first trimester due to lower teratogenic risk compared to methimazole. However, propylthiouracil is associated with potentially severe hepatotoxicity, which can occur unpredictably and is not dose dependent. After completion of organogenesis in the first trimester, methimazole becomes the preferred agent as it has a better safety profile for the mother. Therefore, in the second trimester, all patients on propylthiouracil should be switched to methimazole irrespective of dose or symptom control. In this patient, the presence of elevated liver enzymes further reinforces the need to discontinue propylthiouracil and initiate methimazole to prevent progression to severe liver injury.
- (A) Surgical thyroidectomy in first trimester
- (B) Surgical thyroidectomy in second trimester
- (C) Radioactive iodine therapy in first trimester
- (D) Radioactive iodine therapy in second trimester
💡 Click to Reveal Answer & Nelson Rationale
In pregnant patients with hyperthyroidism who develop serious complications such as agranulocytosis, continuation of antithyroid drugs is contraindicated, necessitating definitive therapy. Surgical thyroidectomy is the preferred option in such cases. The timing of surgery is critical to minimize fetal risk. The second trimester is the safest period because organogenesis is complete, reducing teratogenic risk, and the risk of preterm labor is lower than in the third trimester. Radioactive iodine is contraindicated in pregnancy regardless of trimester, as it crosses the placenta and is concentrated in the fetal thyroid gland, leading to permanent destruction and fetal hypothyroidism. Therefore, second trimester thyroidectomy is the most appropriate management.
- (A) Measure maternal TSH levels weekly and fetal TSH levels monthly
- (B) Measure fetal TSH levels monthly and ultrasound for fetal goiter
- (C) Measure maternal TSH levels monthly and fetal TSH levels weekly
- (D) Serial fetal heart rate monitoring and ultrasound for fetal goiter
💡 Click to Reveal Answer & Nelson Rationale
In pregnant women with Graves’ disease, fetal hyperthyroidism can occur due to transplacental passage of TSH receptor–stimulating antibodies. This process is independent of maternal thyroid hormone levels, so even well-controlled maternal disease does not exclude fetal involvement. Fetal thyrotoxicosis commonly presents with persistent fetal tachycardia, intrauterine growth restriction, and fetal goiter. Therefore, all such pregnancies require structured fetal surveillance using noninvasive methods. Serial monitoring of fetal heart rate helps detect early tachycardia, while ultrasound evaluation is essential to identify fetal goiter and assess growth. Direct measurement of fetal TSH is invasive and not routinely performed. Hence, combined serial fetal heart rate monitoring and ultrasound is the most appropriate approach.
- (A) Transient neonatal thyrotoxicosis followed by drug-induced hypothyroidism
- (B) Neonatal thyrotoxicosis or hypothyroidism
- (C) Persistent neonatal hyperthyroidism with delayed normalization
- (D) Maternal TSH crossing the placenta causing variable neonatal thyroid function
💡 Click to Reveal Answer & Nelson Rationale
Neonates born to mothers with Graves’ disease are exposed to both TSH receptor–stimulating antibodies and antithyroid drugs via transplacental transfer. Immediately after birth, residual maternal antithyroid drugs may suppress neonatal thyroid function, resulting in an initial asymptomatic phase. As these drugs are cleared over the first few days, the effect of circulating maternal stimulating antibodies becomes unopposed, leading to neonatal thyrotoxicosis characterized by tachycardia, irritability, and poor feeding. Subsequently, as maternal antibodies decline and the neonatal thyroid axis remains relatively suppressed or immature, hypothyroidism may develop, presenting with lethargy, constipation, feeding difficulty, and prolonged jaundice. This biphasic and evolving pattern reflects the combined and time-dependent influence of maternal antibodies and drug exposure, and is best described as neonatal thyrotoxicosis or hypothyroidism.
- (A) Universal screening of all pregnant women is recommended
- (B) Serum TSH and free T4 are the primary screening tests in pregnancy
- (C) Trimester-specific TSH reference ranges should be used for screening
- (D) Screening is unnecessary unless symptoms are present
💡 Click to Reveal Answer & Nelson Rationale
Serum TSH is the most sensitive and primary screening test for assessing maternal thyroid status during pregnancy. However, due to physiological changes such as increased human chorionic gonadotropin levels and estrogen-induced rise in thyroxine-binding globulin, normal TSH values vary across trimesters. Therefore, interpretation must be based on population-specific trimester-adjusted reference ranges. The TSH level should be maintained in trimester-specific normal ranges of 0.1 to 2.5 milliunits/L in the first trimester, 0.2 to 3 milliunits/L in the second trimester, and 0.3 to 3 milliunits/L in the third trimester. A TSH value of 3.5 mIU/L at 10 weeks gestation falls above the normal first trimester range and suggests hypothyroidism when interpreted appropriately. Although thyroid disorders are common and associated with adverse outcomes, there is insufficient evidence to universally recommend screening of all pregnant women. Hence, the key principle is correct interpretation of TSH using trimester-specific values rather than nonpregnant reference ranges.
- (A) Thyroid dyshormonogenesis
- (B) Thyroid ectopy
- (C) Thyroid hypoplasia
- (D) Transient hypothyroidism
💡 Click to Reveal Answer & Nelson Rationale
This neonate has features of primary congenital hypothyroidism with low T4 and elevated TSH. The absence of goiter suggests a structural abnormality rather than a hormone synthesis defect. Normal TBG excludes abnormalities in thyroid hormone binding. Serum thyroglobulin reflects the amount of functioning thyroid tissue. In this case, thyroglobulin is low but detectable, indicating the presence of a small amount of thyroid tissue rather than complete absence. This finding favors thyroid hypoplasia over agenesis. Dyshormonogenesis would typically present with goiter and elevated thyroglobulin due to intact but dysfunctional thyroid tissue. Ectopic thyroid usually has preserved or mildly reduced thyroglobulin depending on functional tissue. Transient hypothyroidism does not explain persistent biochemical abnormalities with reduced thyroid tissue.
- (A) TBG deficiency
- (B) Iodine excess
- (C) Liver hemangioma
- (D) Central hypothyroidism
💡 Click to Reveal Answer & Nelson Rationale
This preterm neonate has primary hypothyroidism as evidenced by low T4 and elevated TSH. The presence of a normal-sized, normally located thyroid gland with elevated thyroglobulin indicates intact thyroid tissue with impaired hormone synthesis rather than structural abnormality. The key diagnostic clue is markedly elevated urinary iodine, suggesting excess iodine exposure in the NICU setting. Excess iodine leads to suppression of thyroid hormone synthesis through the Wolff–Chaikoff effect. In preterm infants, the escape from this inhibitory effect is immature, resulting in persistent hypothyroidism. This explains the biochemical pattern along with normal imaging and elevated thyroglobulin. ![[65c7dc29_1778075910712_1778075911.png]] **Table: Interpretation of Thuroid Function Tests and Imaging Results in Congenital Hypothyroidism and Related Disorders** ![[66d02d08_small_table__2__1778132361.png]]
- (A) Start L-thyroxine therapy
- (B) Measure serum cortisol and growth hormone levels
- (C) Measure serum thyroglobulin levels
- (D) Perform radionuclide thyroid scintigraphy
💡 Click to Reveal Answer & Nelson Rationale
This neonate has central hypothyroidism, indicated by low T4 with inappropriately normal TSH and absence of goiter. The presence of hypoglycemia, micropenis, and midline defects strongly suggests associated pituitary hormone deficiencies, possibly due to hypothalamic–pituitary abnormalities such as septo-optic dysplasia. In such cases, evaluating for other hormone deficiencies is critical, particularly cortisol and growth hormone. Identifying cortisol deficiency is essential before initiating thyroid hormone replacement, as starting L-thyroxine without addressing adrenal insufficiency can precipitate life-threatening adrenal crisis. Therefore, evaluation must include assessment of other pituitary hormones, particularly cortisol and growth hormone, along with MRI imaging of the hypothalamic–pituitary region to identify structural abnormalities.
- (A) Congenital hypothyroidism due to thyroid dysgenesis
- (B) Transient hypothyroxinemia of prematurity
- (C) Transient hypothyroxinemia of prematurity
- (D) Sick euthyroid syndrome
💡 Click to Reveal Answer & Nelson Rationale
This extremely premature, critically ill neonate initially had a normal TSH-based newborn screen despite likely low T4 levels, which is characteristic of conditions where TSH elevation is delayed. During the acute illness phase, suppression of the hypothalamic–pituitary–thyroid axis leads to low T4 with normal or low TSH, mimicking sick euthyroid syndrome. As the infant recovers, TSH levels rise, resulting in delayed detection of hypothyroidism. This pattern is termed atypical congenital hypothyroidism or hypothyroxinemia with delayed TSH elevation. It is commonly seen in ELBW infants and may be missed on initial screening, necessitating repeat testing at 2 to 6 weeks.
- (A) Continue dietary management as overall estimated fetal weight is <90th percentile
- (B) Start metformin as add-on therapy due to intermittent postprandial hyperglycemia
- (C) Initiate insulin therapy based on evidence of disproportionate fetal growth
- (D) Defer intervention and repeat fetal biometry after 2 weeks to confirm growth trend
💡 Click to Reveal Answer & Nelson Rationale
In gestational diabetes, fetal abdominal circumference (AC) is a sensitive indicator of fetal hyperinsulinemia and early macrosomia. An AC >70th percentile after 29–30 weeks reflects excessive glucose transfer to the fetus despite apparently acceptable maternal glycemic control. This indicates the need for escalation of therapy. In this case, although estimated fetal weight is within normal range and maternal sugars are borderline controlled, the elevated AC signifies disproportionate fetal growth. Therefore, insulin therapy should be initiated to optimize metabolic control and prevent further complications.
- (A) Appropriate, as early hormonal sampling ensures timely diagnosis before onset of adrenal crisis
- (B) Inappropriate, as hormonal assays are best interpreted when obtained after 48–72 hours of life
- (C) Appropriate, as concurrent electrolyte monitoring compensates for early hormonal sampling
- (D) Inappropriate, as imaging should always precede hormonal evaluation in suspected DSD
💡 Click to Reveal Answer & Nelson Rationale
Evaluation of a newborn with suspected differences in sex development requires careful timing of investigations to ensure accurate interpretation. Hormonal assays such as 17-hydroxyprogesterone, LH, and testosterone are ideally obtained after 48 to 72 hours of life because early postnatal hormonal fluctuations can lead to misleading values. Although early diagnosis is important, especially to detect conditions like congenital adrenal hyperplasia, premature sampling does not improve diagnostic accuracy. Electrolyte monitoring is essential to detect salt-wasting crisis but does not compensate for inappropriate timing of hormonal assays. Imaging studies such as pelvic ultrasonography are useful but do not replace the need for correctly timed hormonal evaluation.
- (A) Swyer’s syndrome due to defective SRY-mediated testicular differentiation with inadequate AMH leading to Müllerian persistence
- (B) External genitalia are typically female but may show subtle virilization due to residual androgen secretion from dysgenetic gonadal elements
- (C) Typically presents at puberty, but may be identified neonatally in cases with internal–external genital discordance
- (D) Approximately 30% tumor risk allows consideration of delayed gonadectomy until after pubertal hormonal contribution
💡 Click to Reveal Answer & Nelson Rationale
This scenario is consistent with 46,XY complete gonadal dysgenesis, where failure of SRY-mediated testicular differentiation leads to deficient Anti-Müllerian hormone and testosterone production. The presence of a uterus confirms lack of AMH effect and persistence of Müllerian structures. External genitalia are typically female due to lack of androgen effect, although mild virilization such as clitoromegaly may occur due to minimal androgen secretion from dysgenetic gonadal elements. While most patients present at puberty with hypergonadotropic hypogonadism, early diagnosis may occur when evaluated for discordance between internal and external genitalia. The risk of germ cell tumors is significant, approximately up to 30%, and current recommendations favor early gonadectomy rather than delaying until after puberty, making the management approach described incorrect.
- (A) 17β-hydroxysteroid dehydrogenase deficiency
- (B) 3β-hydroxysteroid dehydrogenase deficiency
- (C) 5α-reductase deficiency
- (D) 17α-hydroxylase deficiency
💡 Click to Reveal Answer & Nelson Rationale
The presence of palpable gonads and absence of Müllerian structures indicates functional testes with intact Anti-Müllerian hormone production, confirming Sertoli cell activity. Low testosterone with elevated steroid precursors suggests a block in steroidogenesis, pointing toward defects in androgen synthesis. Enzymatic deficiencies such as 17β-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase, and 17α-hydroxylase impair testosterone production at different steps of the steroidogenic pathway and are therefore classified as defects in androgen synthesis. In contrast, 5α-reductase deficiency represents a defect in androgen metabolism, where testosterone is produced normally but cannot be converted to dihydrotestosterone, which is required for external genital virilization. Thus, despite similar clinical presentation, it is not a synthesis defect but a metabolic defect.
- (A) Intramuscular testosterone enanthate 25–50 mg monthly for 3 months
- (B) Initiate intravenous hydrocortisone followed by maintenance glucocorticoid therapy
- (C) Intramuscular testosterone enanthate along with recombinant growth hormone therapy
- (D) Oral testosterone undecanoate 10–20 mg daily for 3 months
💡 Click to Reveal Answer & Nelson Rationale
This is a question requiring differentiation between treatment of life-threatening endocrine deficiency and correction of micropenis. The infant has micropenis with systemic features of panhypopituitarism, including recurrent hypoglycemia and direct hyperbilirubinemia. These findings indicate cortisol deficiency, which is immediately life-threatening and must be addressed urgently. Although micropenis requires treatment with intramuscular testosterone to improve penile length, this is not an emergency intervention. The priority in this clinical setting is stabilization and treatment of adrenal insufficiency with hydrocortisone. Once the infant is clinically stable and life-threatening deficiencies are corrected, androgen therapy can be initiated. Thus, management follows a hierarchy where life-threatening hormone deficiencies are treated before addressing genital abnormalities. Treatment with testosterone enanthate or cypionate 25 to 50 mg intramuscularly given monthly for 3 months may substantially increase the penile length in these patients.
- (A) Plan elective orchidopexy at 6–12 months for the nonpalpable gonad with interval follow-up
- (B) Perform diagnostic laparoscopy to localize the nonpalpable gonad before further evaluation
- (C) Initiate evaluation for disorder of sex development including karyotype and hormonal profile
- (D) Defer evaluation as unilateral undescended testis with hypospadias can be a normal variant
💡 Click to Reveal Answer & Nelson Rationale
This is a confusing scenario combining multiple subtle red flags. The presence of unilateral nonpalpable gonads alone may suggest isolated cryptorchidism, but the addition of proximal hypospadias and a small phallus indicates abnormal androgen exposure or action during fetal life. Even though one testis is palpable and electrolytes are normal, these findings together strongly suggest a possible disorder of sex development. Advanced level reasoning requires recognition that any combination of cryptorchidism with proximal hypospadias or micropenis mandates evaluation for DSD. Imaging findings can be inconclusive early and should not delay biochemical and genetic evaluation. Surgical localization or correction is not the priority until underlying endocrine and genetic causes are assessed.